Clinical features and prognosis analysis of stage III/IV patients with lung cancer after treatment with toripalimab: A real-world retrospective
No Thumbnail Available
Date
2024-12
Journal Title
Journal ISSN
Volume Title
Publisher
Wolters Kluwer – Medknow
Abstract
Aim: Toripalimab is the first antitumor programmed cell death protein 1 (PD‑1) antibody approved in China. For better patient management, it is important to understand the real‑world outcomes of toripalimab in treating patients with lung cancer in the real world outside of clinical trials to improve patient care. Methods: We retrospectively examined the clinical data of 80 patients with lung cancer who received the PD‑1 inhibitor (toripalimab). The Chi‑square test was performed to identify clinical factors associated with the advancement of the disease. Multivariate Cox regression analysis was used to screen prognostic variables linked to real‑world progression‑free survival (PFS) and overall survival (OS). OS and PFS were calculated using the Kaplan‑Meier method, and the comparisons were determined using the log‑rank test, and continuous and categorical variables were explained using median and percentage, respectively. Result: The median OS of the estimated 80 patients was 15.85 months (95% confidence interval [CI]: 14.103–17.949 months), and the estimated PFS was 5.650 months (95% CI: 7.226–11.264 months). The longer OS and PFS correlate with the patient’s staging and number of treatment lines. The PD‑1 drug gave stage III patients a significantly longer PFS and OS compared to stage IV patients (PFS: 14.65 vs. 6.68, P = 0.004; OS: 21.1 vs. 13.7, P = 0.003). First‑ or second‑line immunotherapy patients have significantly longer PFS and OS than third‑ or fourth‑line (PFS: 6.4 vs. 3.6, P = 0.009; OS: 20.0 vs. 10.5, P = 0.003). In patients with stage IV (n = 60) with extensive metastasis, the site of metastasis is mostly 1–3 sites after receiving toripalimab. The duration of PD‑1 inhibitor OS in progressive patients (n = 56) was significantly prolonged (P = 0.038). Conclusion: For patients with lung cancer, toripalimab can considerably extend PFS and OS in the first or second line and in stage III. PD‑1 inhibitors are administered to patients with stage IV extensively metastatic lung cancer, which indicates an oligometastatic progression pattern, primarily in 1–3 locations, who are treated with PD‑1 inhibitors. Continuing toripalimab beyond disease progression significantly prolonged OS.
Description
Keywords
Real‑world, clinical features, lung cancer, prognosis analysis, toripalimab
Citation
Wang Chenlin, Liang Ning, Qiao Lili, Wu Ya’nan, Zhang Jiandong, Zhang Yan. Clinical features and prognosis analysis of stage III/IV patients with lung cancer after treatment with toripalimab: A real-world retrospective. Journal of Cancer Research and Therapeutics. 2024 Dec; 20(7): 2021-2028